Investigating Mitochondrial-Nuclear Communication in AD/ADRD (R01 Clinical Trial Not Allowed)

NIA recently issued an RFA (RFA-AG-25-026) promoting research on nuclear-mitochondrial communication and how this can be altered in AD/ADRD conditions. This Notice of Funding Opportunity (NOFO) invites R01 applications that investigate mitochondrial-nuclear communication in the context of neurobiology and Alzheimer's disease (AD) and AD-related dementias (AD/ADRD). This research will transform our understanding of how mitochondrially derived metabolites can impact nuclear gene expression and how changes to nuclear function can impact mitochondrial activity. This has the potential to serve as the foundation for the development of future AD/ADRD therapies that specifically target mitochondrial function as well as shed light on the role that mitochondria play in aging and neurodegeneration.

Applications can be submitted starting October 7, 2024.